Martin MacKay

Martin MacKay

Fondateur chez RALLYBIO CORPORATION

Fortune : 4 M $ au 30/04/2024

68 ans
Commercial Services
Health Technology
Technology Services

Profil

Martin W.
MacKay
is the founder and currently holds the position of Chairman & Chief Executive Officer at Rallybio LLC, which was founded in 2018.
He is also the Executive Chairman at Rallybio Corp., founded in 2018.
In addition to his founding positions, Dr. MacKay currently serves as the Chief Executive Officer at Calyx Group Ltd.
(Ireland) and Rallybio Holdings LLC.
He is also a Director at Charles River Laboratories International, Inc., an Independent Director at Charles River Laboratories, Inc., and an Independent Director at Novo Nordisk A since 2018.
Dr. MacKay has held former positions as the Chief Executive Officer at Vecta Software Corp.
Ltd., Neverfail, Inc., and Neverfail Ltd.
He was also a Director at Encysive Pharmaceuticals, Inc. in 2008.
Additionally, he has served as the Operations Director at The Dun & Bradstreet Corp.
and Director-Business Development at NorthgateArinso, Inc. Dr. MacKay was an Independent Director at 5:01 Acquisition Corp.
from 2020 to 2022.
He held the position of Senior Vice President-Worldwide Development at Pfizer Inc. from 1995 to 2009 and President-Research & Development at AstraZeneca PLC from 2010 to 2013.
From 2013 to 2017, he was the Global Head-Research & Development at Alexion Pharmaceuticals, Inc. Dr. MacKay has also held positions at VeriSign, Inc., BASF Performance Products Ltd.
(United Kingdom), New Leaf Venture Partners LLC, Pfizer (St. Louis), CRI Worldwide LLC, PeopleSoft USA, Inc., Accenture LLC, Ciba-Geigy Pharmaceuticals, and Beecham Pharmaceuticals (UK).
Dr. MacKay obtained a doctorate degree from The University of Edinburgh in 1984 and an undergraduate degree from Heriot-Watt University in 1979.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
13/05/2024 12 531 ( 0,02% ) 3 M $ 30/04/2024
31/03/2024 719 126 ( 1,90% ) 1 M $ 30/04/2024

Postes actifs de Martin MacKay

SociétésPosteDébut
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Directeur/Membre du Conseil 05/07/2017
NOVO NORDISK A/S Directeur/Membre du Conseil 01/03/2018
RALLYBIO CORPORATION Fondateur 01/01/2018
Directeur/Membre du Conseil -
Directeur Général -
Directeur Général 01/01/2018
Directeur Général 22/12/2010
Tous les postes actifs de Martin MacKay

Anciens postes connus de Martin MacKay

SociétésPosteFin
501 ACQU Directeur/Membre du Conseil 22/04/2022
ALEXION PHARMACEUTICALS, INC. Directeur Technique/Scientifique/R&D 01/06/2017
░░░░░░░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ -
░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
Voir l'expérience en détail de Martin MacKay

Formation de Martin MacKay

The University of Edinburgh Doctorate Degree
Heriot-Watt University Undergraduate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Martin MacKay

Relations

100 +

Relations au 1er degré

28

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Sociétés cotées6
PFIZER, INC.

Health Technology

ASTRAZENECA PLC

Health Technology

VERISIGN. INC.

Technology Services

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Commercial Services

NOVO NORDISK A/S

Health Technology

RALLYBIO CORPORATION

Health Technology

Entreprise privées20

Technology Services

Commercial Services

Health Technology

Health Technology

Communications

Process Industries

Commercial Services

Commercial Services

Technology Services

Technology Services

Technology Services

Health Technology

Beecham Pharmaceuticals (UK)

Ciba-Geigy Pharmaceuticals

Commercial Services

Commercial Services

Health Services

Commercial Services

Finance

Finance

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Martin MacKay
-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.
PROFITEZ-EN MAINTENANT